Related Experiment Video
Updated: May 31, 2026

Defining Substrate Specificities for Lipase and Phospholipase Candidates
Published on: November 23, 2016
Targeting phosphatidylcholine-specific phospholipase C for atherogenesis therapy
HaiYing Li1, Lu Zhang, DeLing Yin
1Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology, Institute of Developmental Biology, School of Life Science, Shandong University, Jinan 250100, China.
Abstract:
Atherosclerosis, a dynamic and progressive vascular disease arising from the combination of endothelial dysfunction and inflammation, is becoming a major killer in the 21st century. Accumulating evidence implicates phosphatidylcholine-specific phospholipase C (PC-PLC) in endothelial dysfunction and several inflammation processes. In addition, in a recent study, we demonstrated that PC-PLC contributed to the progression of atherosclerosis. Considering the important roles of PC-PLC in vascular endothelial cell dysfunction and its proinflammatory properties, we propose that a pharmacological blockade of PC-PLC represents a rational approach to atherosclerosis therapy.
Related Concept Videos
Synthesis of Phosphatidylcholine in the ER Membrane
The major components of all eukaryotic cell...
Atherosclerosis III: Management
Pharmacogenomics: Identification of New Drug Targets
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis I: Introduction
